Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy

Table 1 Statins, cirrhosis decompensation, hepatocellular carcinoma and mortality

Ref.	Groups, n	Follow up	Risk reduction
Mohanty et al[50], 2016	Statins 1323; Nonusers 12522	Approximately 2.5 yr for statin; Approximately 2.5 yr for nonusers	Cirrhosis decompensation and mortality
Huang et al[51], 2016	Statins 6543; Nonusers 6543	4.7 yr for statins; 4.6 yr for nonusers	Cirrhosis decompensation
Chang et al[52], 2017	Statins 1174; Nonusers 6453	Approximately 3.0 yr	Cirrhosis decompensation, HCC, and mortality
Kumar et al[53], 2014	Statins 81; Nonusers 162	Approximately 3.0 yr for statin; Approximately 1.5 yr for nonusers	Cirrhosis decompensation and mortality
Bang et al[54], 2017	Statins 794; Nonusers 4623	Approximately 4.0 yr	Cirrhosis decompensation and mortality

HCC: Hepatocellular carcinoma.